ClinicalTrials.gg

Neurodegenerative Diseases clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 436 studies for Neurodegenerative Diseases across more than 10 countries. 143 are recruiting or about to start. 86 of them are mainly about Neurodegenerative Diseases (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 51 narrower conditions too, such as Parkinson Disease: 12,921 studies, 3,193 open.

Status

Completed
182
Recruiting
101
Status unknown
34
Active, not recruiting
30
Terminated
29
Not yet recruiting
25

Phase

Phase 2
83
Phase 1
54
Phase 3
32
Early Phase 1
5
Phase 4
3

Where

United States
176
Italy
67
France
67
United Kingdom
50
Germany
49
Spain
43

Who develops what

Add Neurodegenerative Diseases to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 11 programs from 10 companies, 0 with this as their studies’ main aim; 2 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Eli Lilly, H. Lundbeck and Neurocrine Biosciences here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
DexamethasoneRecent, limited
Evidence
  • NCT05738486 · Eli Lilly and Company · Phase 3 · live · background · “Dexamethasone” · registered Feb 2023
AbbVie11% of its industry studiesUS: off-patent, 28 generics marketedEU: Norgine (EMA 2016)11 study
RiluzoleRecent, limited
Evidence
  • NCT05508074 · InFlectis BioScience · Phase 2 · background · “Riluzole 100mg/day” · registered Jul 2022
Sanofi33% of its industry studiesUS: off-patent, 3 generics marketedEU: Sanofi (EMA 1996) + 1 other11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 11 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 2 Feb 2027 est.VX-670 · Vertex Pharmaceuticals Incorporated · Phase 2 named, not the main aimNCT06185764 A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) — primary endpoint: Parts A and B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) · 47 enrolled
  • Jun 2027 est.VIM0423 · Vima Therapeutics · Phase 2 named, not the main aimNCT07804615 A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy — primary endpoint: Change from baseline in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) · 80 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Neurodegenerative Diseases studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Dopamine agonists 7 · Cholinesterase inhibitors 4

Coming up

41studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 101 Neurodegenerative Diseases studies recruiting now, 52 (51%) set no upper age limit and 11 (11%) stop at 75 or younger. 20 (20%) take children under 18. 1 (1%) are for women only and 0 (0%) for men only; 49 (49%) take healthy volunteers.

Recruiting studies that take each age, of 101
AgeWomenMen
1019 (19%)19 (19%)
1859 (58%)58 (57%)
3069 (68%)68 (67%)
4077 (76%)76 (75%)
5088 (87%)87 (86%)
6597 (96%)96 (95%)
7593 (92%)92 (91%)
8573 (72%)72 (71%)

Across all 436 studies, recruiting or not: 15% stop at 75 or younger and 5% at 65; 15% take children; 1% are for women only and <1% for men only; 32% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Neurodegenerative Diseases studies take

Of 35 phase 2 interventional studies under Neurodegenerative Diseases, half reached primary completion within 30 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 122 mo11–41 · 29 studies——
Phase 230 mo22–47 · 35 studies——
Phase 353 mo34–56 · 16 studies——
Interventional, no phase35 mo11–67 · 82 studies—35 mo10–57 · 75 studies
Observational94 mo39–216 · 82 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 436. Browse all 436 → or search them.